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1. Introduction
  Toxoplasma gondii (T. gondii) is an opportunistic 
parasitic infection in immune compromised hosts and 
estimates indicate that up to one third of the world’s human 
population is infected[1]. Although toxoplasmosis occurs 
worldwide, the seroprevalence of T. gondii infection can 
vary greatly between countries (10%-80%) and even within 
a given country[2,3]. People are infected by three principal 
routes of transmission: foodborne transmission (consuming 
undercooked, contaminated meat), animal-to-human 
transmission (ingesting oocysts shed in the feces of infected 
cats), and vertical transmission from mother to fetus through 
the placenta during pregnancy. Additionally, T. gondii can 
be transmitted via blood transfusion or organ transplantation 
from infected donors[4,5]. 
  Toxoplasmosis most commonly manifests as a mild, 
flu-like illness with low-grade fever, myalgia, malaise, 
and headache, but primary infection in humans 
may also cause spontaneous abortion, fetal mental 
and psychomotor retardation, retino-choroiditis, 
encephalitis, and hepatitis[6,7]. Infections with T. gondii 
are usually fatal in immunocompromised hosts unless 
the infection is recognized and treated[8]. Toxoplasmosis 
in the immunocompromised host is mostly due to the 
consequence of reactivation of disease acquired before 
immunosuppression occurred[9]. 
  It is known that toxoplasmosis rarely leads to various 
liver pathologies, most common of which is granulomatous 
hepatitis in patients having normal immune systems. 
Patients who have cirrhosis of the liver are subjected to a 
variety of cellular as well as immunity disorders. Therefore, 
opportunistic toxoplasmosis can cause more frequent and 
severe diseases in patients with cirrhosis and is capable of 
changing the course of the disease[10].
  Some studies have reported an increased prevalence 
of antibodies against T. gondii among liver disease 
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patients[10,11]. An association of T. gondii infection with liver 
cirrhosis has been reported in a previous epidemiological 
study[12].
  Due to lack of information about the association of 
Toxoplasma infection and HCV infection in patients with 
chronic liver disease, this case-control study was performed 
to determine the seroprevalence of anti-T. gondii IgG and 
IgM levels in adult patients with chronic hepatitis C patients 
and to study the possible association of toxoplasmosis with 
deterioration  of the liver condition.
2. Material and methods
2.1. Study population
  A case control study was conducted from May 2010 
through May 2012 at Tropical medicine Department, 
Mansoura University Hospital, Egypt. The study included 
120 adult chronic liver disease patients, 81 HCV patients 
with decompensated cirrhosis (late-stage), 39 chronic HCV 
non cirrhotic patients (early-stage) and 40 healthy blood 
donors as controls from same region matched by gender 
and age. Clinical examination for the study subjects was 
done. Institutional ethical clearance and appropriate written 
informed consent was obtained from each participant.
2.2. ELISA for anti-Toxoplasma antibodies
  Subjects of the study were examined with enzyme-
linked immunoassays for anti-Toxoplasma IgG and anti-
Toxoplasma IgM antibodies. Samples were tested for both 
anti-T. gondii IgM and IgG antibodies using (IMMUNOSPEC, 
CA, USA) kit which detects antibodies against highly 
purified native Toxoplasma antigens. In both procedures, the 
manufacturer guidelines were followed. For interpretation 
of semiquantitative detection of IgG-class antibodies to 
T. gondii, a graph is constructed by blotting the U/mL 
against the average OD of the controls; when the OD of the 
samples is reported on the graph, the U/mL contained in the 
serum samples can be calculated. A standard curve must 
be performed for each run. The results are expressed in IU 
and a result equal or greater than 10 U/mL was considered 
positive.
2.3. Real-Time PCR for early stage HCV patients
  HCV RNA was extracted from 140 毺L of each serum 
sample using a QIAamp Viral RNA Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. 
RNA was eluted in 60 毺L of elution buffer and stored at -20 曟.
Quantification of extracted HCV RNA were performed on a 
Mx3000P™ Real-Time PCR System (Stratagene,  La Jolla, CA) 
using a TaqMan® OneStep RT-PCR Master Mix Reagents 
Kit (Applied Biosystems, Foster City, CA). HCV RNA was 
amplified according to the following program: 1 cycle each of 
48 曟 for 30 min and 95 曟 for 10 min, followed by 40 cycles 
each of 95 曟 for 15 s and 60 曟 for 1 min. The threshold 
cycle values from samples were plotted on the standard 
curve and the numbers of copies were automatically 
calculated. For each run, positive and negative controls were 
included[13].
2.4. Liver biopsy, this was done for the early stage HCV 
patients
  Liver biopsy was performed according to the consensus 
recommendations of the Asian Pacific Association for the 
Study of the Liver[14,15]. Written consent was taken from all 
patients before taking the liver biopsy. Liver histology was 
graded and staged according to Ishak fibrosis scaling system 
that classifies fibrosis into five stages (F0-F4) and activity 
into four grades A0-A3[16].
2.5. Statistical analysis
  Data entry and analysis was performed using SPSS 16.0 
(SPSS Inc., Chicago, IL.). Summaries were presented in terms 
of mean, range and percentage as appropriate. Differences 
in proportions were evaluated by Pearson’s Chi-square test. 
A statistical test result was considered significant whenever 
a P<0.05.
3. Results
  A total of 120 adult chronic liver disease patients, 81 
decompensate cirrhosis (late-stage) with mean age (52.33依
6.76) years, 39 chronic HCV non cirrhotic patients (early-
stage) with mean age (43.44依8.58) years in addition to 40 
healthy blood donors as controls with mean age of (40.67
依11.00) years were enrolled in this study. Clinical and 
laboratory data are shown in (Table 1&2). Clinically, the 
difference in the liver and spleen size between groups was 
statistically significant, P<0.001. No correlation was detected 
among groups regarding ascites or focal lesion. Concerning 
liver function tests (ALT, AST, serum albumin, billirubin 
level and prothrombine time); significant correlation was 
detected only between billirubin level and anti-T. gondii 
IgG in the late group (r=0.245 & P=0.027).
  Anti-T. gondii IgG antibodies were detected in 75 (92.6%) of 
81 late-stage cirrhotic patients, 30 (76.9%) of the 39 chronic 
HCV non cirrhotic patients (early-stage) and in 6 (15%) of 
40 controls (Table 3). There is a statistically significance 
between positivity of anti-T. gondii IgG antibodies between 
3 groups (P<0.001). In the late-stage group; of the 75 
anti-T. gondii IgG positive patients, 32 (39.5%) had IgG 
levels higher than 150 IU/mL suggestive of prior infection, 
and 29 (35.8%) between 8 to 99 IU/mL. In the early-stage 
group; of the 30 anti-T. gondii IgG positive patients, 17 
(43.6%) had IgG levels higher than 150 IU/mL, and 7 (17.9%) 
between 8 to 99 IU/mL. 
  Anti-T. gondii IgM antibodies were detected in 11 (13.6%) 
in late stage patients, in 5 early stage-patients (12.8%) and in 
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3 (7.5%) of controls with no statistical significant difference, 
P=0.610 (Table 3).
  There was no correlation between stage of fibrosis and 
presence of IgM or IgG antibodies levels in our studied 
groups (P=0.576 and 0.526 respectively) (Tables 4). Presence 
of high IgG levels was significantly correlated with high viral 
loads levels (P=0.026) (Table 5).
4. Discussion 
  Toxoplasmosis is a protozoan disease that is widespread 
all over the world and demonstrates varying clinical 
manifestations. Determination of its incidence in various risk 
groups in the society and establishment of these risk groups 
play a significant role in taking the necessary precautions 
against this disease[12].
  In this study Toxoplasma ELISA antibody positivity was 
significantly higher in cirrhotic patients. We found a higher 
frequency of anti-T. gondii IgG and IgM antibodies in 
chronic HCV patients than healthy blood donors  controls. 
Previous reports about the association of T. gondii infection 
in liver disease patients in Egypt and other countries 
are scarce. The high level of anti-T. gondii IgM and IgG 
levels in cirrhotic patients than in healthy control may be 
explained by the occurrence of  humoral and cell-mediated 
immunity defects in chronically infected patients with 
consequent reactivation of latent infection[17,18]. Our results 
Table 1




Late (%) Early (%) Control (%)
Focal lesion Negative 65 (45.1) 39 (27.1) 40 (27.8) 144
Positive   16 (100.0) - -        16
Splenomegaly* Negative   9 (11.3) 31 (38.8) 40 (50.0)  80
Mild 57 (90.5) 6 (9.5) -  63
Moderate 10 (83.3)   2 (16.7) -  12
Sever     5 (100.0) - -    5
Ascitis Negative 27 (25.5) 39 (36.8) 40 (37.7) 106
Mild   15 (100.0) - -   15
Moderate   22 (100.0) - -   22
Sever   17 (100.0) - -   17
Liver**  Average 32 (28.8) 39 (35.1) 40 (36.0) 111
Enlarged     3 (100.0) - -    3
Shrunken  46 (100.0) - -  46
*There a statistical significance between groups regarding splenomegaly (P<0.001), **There a statistical significance between groups regarding 
liver size (P<0.001).
Table 2
Laboratory data of chronic HCV patients and control.
Variable Mean Std. deviation Std. error
95% confidence interval for means
P value
Lower bound Upper bound
Albumin Late   2.771   0.655 0.073   2.626   2.916 0.001
Early   4.228   0.465 0.074   4.077   4.378
Bilirubin Late   2.565   1.661 0.184   2.198   2.932 0.001
Early   0.805   0.194 0.031   0.742   0.868
ALT Late 41.803 25.574 2.842 36.148 47.457 0.260
Early 47.974 32.400 5.188 37.472 58.477
AST Late 57.370 32.513 3.613 50.181 64.560 0.068
Early 45.923 30.462 4.878 36.049 55.798
PT Late 64.593 13.802 1.534 61.541 67.645 0.001
Early 86.487 10.190 1.632 83.184 89.790
Table 3
Anti-T. gondii IgG  and IgM antibodies in the study groups.
Group
IgG IgM
Positive(%) Negative (%) Positive (%) Negative (%) 
Early (n=39) 30(76.9)   9(23.1)   5(12.8) 34(87.2)
Late (n=81) 75(92.6) 6(7.4) 11(13.6) 70(86.4)
Control (n=40)   6(15.0) 34(85.0) 3(7.5) 37(92.5)
P value 0.001 0.610
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coincides with that reported in an early Egyptian study 
where a 65.5% seroprevalence of T. gondii antibodies were 
detected in patients with acute and chronic hepatic diseases 
against a 27% seroprevalence found in controls[19] and a 
Turkish study where researchers found an association of
T. gondii infection with liver cirrhosis[12]. Our results conflict 
with those reported in a Mexican study where most of their 
patients suffered from liver disese but they did not find any 
association between seropositivity to T. gondii and cirrhosis 
with comparable seroprevalence of T. gondii IgM and IgG 
levels in patients and controls[10]. This difference could be 
attributed to the inclusion of liver disease patients due to 
many causes (alcoholic and HCV liver cirrhosis, steatosis, 
chronic hepatitis, acute hepatitis and amoebic liver abscess) 
and not confined to only HCV infected group in that 
study. Each cause of liver disease has different impact on 
immunological and pathological sequel.     
  In this study, 6 (15%) out of the 40 blood donor control, had 
anti-T. gondii IgG, 3 (7.5%) of them had IgG levels higher 
than 150 IU/mL, and 9 (22.5 %) between 8 to 99 IU/mL.
Compared to other countries, our overall seroprevalence 
within blood donors was lower than seroprevalence reported 
in blood donors from countries including Mexico[20], 
Brazil[21], Chile[22], Malaysia[23], India[24], Egypt[25] and New 
Zealand[26], where seroprevalences varied from 20.3% to 
75.0%. The relatively low overall seroprevalence in Egypt is 
probably because the majority of the population eats well-
cooked food.
  As blood transfusion is a potential transmission route 
for Toxoplasma infection, some studies suggest that 
toxoplasmosis transmitted through blood transfusion 
could lead to  ser ious  c l inical  consequences  in 
immunocompromised patients and multiple blood 
transfusion recipients. Patients with liver cirrhosis are 
more susceptible to this risk in particular as they may need 
frequent blood transfusion for correction of severe anemia 
or hemodynamic resuscitation following repeated attacks of 
haematemesis[27]. However, routine screening for T. gondii in 
blood and blood products is not mandatory in Egypt. In our 
study, 3 (7.5%) of controls blood donors had IgM antibodies 
against T. gondii. This may one of the explanations for the 
high prevalence of anti T. gondii IgG and IgM in our cirrhotic 
patients. Therefore, blood donors with an acute phase of 
infection could be excluded from donation especially in 
absence of exclusion of Toxoplasma parasitemia by real-
time PCR. This may be a good preventive measure especially 
if the recipient is an immunocompromised like cirrhotic 
patients[28].
  The current study revealed that there was no correlation 
between stage of fibrosis and presence of IgM or IgG 
antibodies. Our results does not support the concept that 
the number of activated hepatic satellite cells (HSCs, 
which is responsible for hepatic fibrosis) was significantly 
higher in the T. gondii infection groups than that in the 
healthy group which may represent an active role of HSCs 
in liver pathology and the pathobiology of T. gondii-
related hepatitis[29]. In the current study, compensated 
early cirrhotic patients showed high IgG levels that were 
significantly correlated with high viral loads levels (P=0.026), 
while moderate and high viral load levels were significantly 
correlated with absence of IgM antibodies (P=0.026). 
  These results are supported by the fact that depletion of 
CD4 and CD8 T cells during chronic infection with viruses 
like HCV results in parasite reactivation[30,31], and it may 
be the same etiology causing high viral replication in 
our chronic HCV patients with high IgG titer.  While the 
association of low viral load and negative IgM levels are 
sign of both viral and parasitic clearance and this may be 
a reflection to the immune status of the patients. It is worth 
mentioning that patients with AIDS and serum anti-HCV 
positivity had an increased prevalence of antibodies against 
hepatitis B virus, T. gondii and Cytomegalovirus as opposed 
to a lower frequency of serum autoantibodies[11]. 
  This study highlights that T. gondii is more prevalent 
among cirrhotic patients than in healthy blood donors. 
Since blood transfusion is a potential transmission route for 
Table 4
Correlation between stage of fibrosis and presence of IgM & IgG antibodies.
 Liver fibrosis 
IgM IgG
Total
Negative Positive Negative Positive 
Mild (F1-F2) (%) n=27 23(85.2)   4(14.8) 7(25.9) 20(74.1) 27(100.0)
Severe (F3-F4)(%) n=12 11(91.7) 1(8.3) 2(16.7) 10(83.3) 12(100.0)
Total 34 5 9 30 39
P value 0.576 0.526
Table 5




Negative Positive Negative Positive 
Low (< 100.000) n(%) 1(11.1)   5(16.7) 3(8.8)    3(60.0)   6(15.4)
Mild (100.000 -400.000) n(%) 5(55.6)   3(10.0)   7(20.6)    1(20.0)   8(20.5)
Moderate (400.000-800.000) n(%) 2(22.2)   9(30.0) 10(29.4)    1(20.0) 11(28.2)
High (>800.000) n(%) 1(11.1)  13(43.3) 14(41.2)   0(0.0) 14(35.9)
Total n(%)   9(100.0)    30(100.0)   34(100.0)       5(100.0)    39(100.0)
P value           0.026           0.022
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Toxoplasma infection, patients with liver cirrhosis are likely 
to form a Toxoplasma risk group. 
  Limitations of the study: repeated investigations following 
anti-Toxoplasma-treatment, especially viral load, needs 
to be done in patients with both high viral load and high 
Toxoplasma antibodies, to confirm this comorbidity.
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